TY  - GEN
AU  - Gavila, Joaquin
AU  - Oliveira, Mafalda
AU  - Pascual, Tomas
AU  - Perez-Garcia, Jose
AU  - Gonzalez, Xavier
AU  - Canes, Jordi
AU  - Pare, Laia
AU  - Calvo, Isabel
AU  - Ciruelos, Eva
AU  - Munoz, Montserrat
AU  - Virizuela, Juan A
AU  - Ruiz, Isabel
AU  - Andres, Raquel
AU  - Perello Martorell, Antonia
AU  - Martinez, Jeronimo
AU  - Morales, Serafin
AU  - Marin-Aguilera, Mercedes
AU  - Martinez, Debora
AU  - Quero, Juan C
AU  - Llombart-Cussac, Antonio
AU  - Prat, Aleix
PY  - 2019
DO  - 10.1186/s12916-018-1233-1
SN  - 1741-7015
UR  - https://hdl.handle.net/20.500.12105/22652
AB  - BackgroundThe Opti-HER HEART trial aimed to optimize activity while minimizing cardiac risk by combining trastuzumab, pertuzumab, and paclitaxel with non-pegylated liposomal doxorubicin in the treatment of HER2-positive early breast...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Breast cancer
KW  - PAM50
KW  - HER2
KW  - Intrinsic subtypes
KW  - Cardiac safety
KW  - HER2-enriched
KW  - Neoadjuvant
KW  - Breast Neoplasms
KW  - Aged
KW  - Doxorubicin
KW  - Neoadjuvant Therapy
KW  - Polyethylene Glycols
KW  - Trastuzumab
KW  - Adult
KW  - Humans
KW  - Antibodies, Monoclonal, Humanized
KW  - Cardiotoxicity
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
KW  - Receptor, ErbB-2
KW  - Female
KW  - Paclitaxel
KW  - Chemotherapy, Adjuvant
TI  - Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
TY  - research article
ER  -